Interim Results For The Six Months Ended 31 March 2006

 

Interim Results For The Six Months Ended 31 March 2006

20  June  2006

Porton Down, UK, 20 June 2006: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new medicines based on cannabis and other controlled drugs, announces its interim results for the six months ended 31 March 2006. GW today is also hosting a research and development (R&D) day for analysts and investors.

HIGHLIGHTS

 

Dr Geoffrey Guy, Executive Chairman of GW, said:

"GW is now generating product sales revenues in Canada, Spain and the UK. In addition, we are increasingly excited by the prospects for Sativex in the US following the FDA’s permission to enter directly into Phase III trials. GW has a broad development and regulatory strategy for Sativex which provides multiple opportunities over the next few years to continue to obtain product approvals in various indications across Europe, North America and beyond. In the nearer term, we will continue our regulatory discussions in Europe to determine the initial target indication for our next regulatory filing , report results of two further European Phase III studies and start our first pivotal study in the US. With these important value drivers to come, we believe the prospects for GW are extremely encouraging."

An analyst presentation of the interim results and an R&D day are being held today from 09.30 at Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB. Please contact Gemma Cross Brown at Financial Dynamics on +44 20 7269 7125 for details. An audio webcast of the presentation will be available on GW’s website at www.gwpharm.comlater this afternoon.

Enquiries:
GW Pharmaceuticals plc  Today: +44 (0)20 7831 3113

Dr Geoffrey Guy, Executive Chairman  (Thereafter) + 44 1980 557000

Justin Gover, Managing Director  

Financial Dynamics  Tel: +44 (0)20 7831 3113

David Yates / Sarah Macleod

View the complete document[PDF, 144KB, opens in a new window].

To view this document you will need Adobe Acrobat Reader. Download this software.